Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients ...

Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn ...

Verona Pharma (NASDAQ:VRNA)'s stock has reached an unprecedented peak, setting an all-time high at $56.49. This milestone underscores a remarkable period of growth for the $4.49 billion ...

For instance, the approval of Verona Pharma’s Ohtuvayre by the U.S. Food and Drug Administration (FDA) provided a much-needed non-steroid inhaled treatment option for patients with chronic obstructive ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in the U.S., Canada, Europe, and Japan before Akeso's news broke. The company ...

First shared at a recent Japanese Society of Digital Pathology meeting, the company is forging a global alliance with a leading US medical institution and other organizations to harness technology for ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...